In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic.
AUTOR(ES)
Niki, Y
RESUMO
The in vitro and in vivo antichlamydial activities of HSR-903 were investigated. The MICs of HSR-903 for different species of chlamydia were 0.016 to 0.063 microg/ml, which were superior to those of conventional fluoroquinolones. The therapeutic effect of HSR-903 in experimental mouse Chlamydia psittaci pneumonia was also excellent and almost equal to that of minocycline and superior to that of ofloxacin. These results indicate that HSR-903 may be useful in the treatment of respiratory infections caused by chlamydiae.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=163811Documentos Relacionados
- In Vivo Activity of HSR-903, a New Fluoroquinolone, against Respiratory Pathogens
- In vitro activity of HSR-903, a new quinolone.
- Effect of HSR-903, a New Fluoroquinolone, on the Concentration of Theophylline in Serum
- In Vitro Activity of HSR-903, a New Oral Quinolone, against Bacteria Causing Respiratory Infections
- In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibiotic.
